With Gamifant now as the first FDA-approved treatment for MAS, we have a new therapeutic option that helps control hyperinflammation and reduce our reliance on high-dose glucocorticoids." ...

As for Gamifant, this IP is indicated for primary hemophagocytic lymphohistiocytosis (HLH) and generated 9.0% of BIOVF’s total Q1 revenues, and grew a whopping 31% YoY.

Sobi® (STO: SOBI), today announced a research collaboration involving a new Phase 2a clinical trial for Gamifant® (emapalumab) for the potential treatment of interferon-gamma (IFNγ)-driven ...

Nov 20 (Reuters) - Swedish Orphan Biovitrum AB (publ) : * FDA APPROVES GAMIFANT® (EMAPALUMAB-LZSG), THE FIRST AND ONLY TREATMENT INDICATED FOR PRIMARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH) ...

Gamifant, an interferon gamma (IFNγ)–blocking antibody, is the first and only FDA approved treatment for adult and pediatric (newborn and older) patients with primary HLH with refractory ...

Approval based on the pooled analysis of our pivotal EMERALD and NI-0501-06 studies, showing 54% of patients treated with Gamifant achieved complete response at week 8. STOCKHOLM, June 28, 2025 ...

Gamifant ® (emapalumab-Iszg) is an interferon gamma (IFNγ)-blocking antibody indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic ...